- Home
- DMAC vs PESI Comparison
DMAC vs PESI Comparison
Compare DMAC & PESI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMAC
- PESI
- Stock Information
- Founded
- DMAC 2000
- PESI 1990
- Country
- DMAC United States
- PESI United States
- Employees
- DMAC N/A
- PESI N/A
- Industry
- DMAC Biotechnology: Pharmaceutical Preparations
- PESI Environmental Services
- Sector
- DMAC Health Care
- PESI Industrials
- Exchange
- DMAC Nasdaq
- PESI Nasdaq
- Market Cap
- DMAC 158.1M
- PESI 176.5M
- IPO Year
- DMAC N/A
- PESI 1992
- Fundamental
- Price
- DMAC $4.11
- PESI $10.59
- Analyst Decision
- DMAC Strong Buy
- PESI Strong Buy
- Analyst Count
- DMAC 2
- PESI 1
- Target Price
- DMAC $8.00
- PESI $18.00
- AVG Volume (30 Days)
- DMAC 102.4K
- PESI 186.1K
- Earning Date
- DMAC 05-13-2025
- PESI 05-08-2025
- Dividend Yield
- DMAC N/A
- PESI N/A
- EPS Growth
- DMAC N/A
- PESI N/A
- EPS
- DMAC N/A
- PESI N/A
- Revenue
- DMAC N/A
- PESI $59,419,000.00
- Revenue This Year
- DMAC N/A
- PESI $23.71
- Revenue Next Year
- DMAC N/A
- PESI $86.33
- P/E Ratio
- DMAC N/A
- PESI N/A
- Revenue Growth
- DMAC N/A
- PESI N/A
- 52 Week Low
- DMAC $2.14
- PESI $6.25
- 52 Week High
- DMAC $6.82
- PESI $16.25
- Technical
- Relative Strength Index (RSI)
- DMAC 50.90
- PESI 66.12
- Support Level
- DMAC $3.92
- PESI $10.00
- Resistance Level
- DMAC $4.33
- PESI $11.33
- Average True Range (ATR)
- DMAC 0.29
- PESI 0.58
- MACD
- DMAC 0.02
- PESI 0.04
- Stochastic Oscillator
- DMAC 56.79
- PESI 66.96
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
About PESI Perma-Fix Environmental Services Inc.
Perma-Fix Environmental Services Inc is a provider of both nuclear services and the management of nuclear and mixed waste. The company operates through two segments: The treatment segment offers nuclear, low-level radioactive, Mixed, hazardous and non-hazardous waste treatment, processing and disposal services, and the Services segment which generates the majority of the revenue, provides on-site waste management services to commercial and government customers, technology-based services, construction, logistics, and transportation services among others.